Context Therapeutics (NASDAQ:CNTX) Stock Bumped Down to “Strong Sell” by Zacks Research

Zacks Research downgraded shares of Context Therapeutics (NASDAQ:CNTX) from a hold rating to a strong sell rating in a research report report published on Monday morning,Zacks reports.

Other equities analysts have also recently issued reports about the stock. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Lifesci Capital cut shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Maxim Group lowered their price objective on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Finally, Weiss Ratings lowered shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

Context Therapeutics Stock Down 9.8%

CNTX opened at $0.28 on Monday. The firm has a market cap of $25.27 million, a price-to-earnings ratio of -0.57 and a beta of 1.71. Context Therapeutics has a 52 week low of $0.27 and a 52 week high of $3.62. The business’s 50 day moving average is $0.40 and its two-hundred day moving average is $1.22.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). Equities analysts expect that Context Therapeutics will post -0.45 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CNTX. Sanctuary Advisors LLC acquired a new position in shares of Context Therapeutics in the first quarter valued at approximately $51,000. Squarepoint Ops LLC acquired a new position in Context Therapeutics in the 2nd quarter valued at $29,000. Bank of America Corp DE acquired a new position in Context Therapeutics in the 2nd quarter valued at $30,000. Two Sigma Securities LLC raised its position in Context Therapeutics by 388.7% during the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after buying an additional 48,871 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new position in Context Therapeutics during the 1st quarter worth $211,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.